A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,020

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Chronic Kidney Disease
Interventions
DRUG

Placebo

9g /day (3 times a day)

DRUG

AST-120

9g /day (3 times a day)

Trial Locations (105)

Unknown

Phoenix

Little Rock

Alhambra

Covina

Glendale

Los Angeles

Stamford

Washington D.C.

Hudson

Miami

Ocala

Orlando

Pembroke Pines

Spring Hill

Tampa

Winter Park

Kansas City

New Orleans

Shreveport

Ypsilanti

Kansas City

St Louis

Camden

Eatontown

Port Washington

Springfield Gardens

Asheville

Cincinnati

Dayton

Toledo

Portland

Philadelphia

Pittsburgh

Rock Hill

Nashville

Arlington

Dallas

Houston

San Antonio

Appleton

Oshkosh

Buenos Aires

Córdoba

San Luis

San Miguel de Tucumán

San Pedro

Barao Geraldo-Campinas

Belo Horizonte Minas Gerais

Juiz de Fora

Porto Alegre

Rio de Janeiro

São Paulo

Taubaté

Winnipeg

Brampton

Kitzhener

Oakville

Scarborough Village

Toronto

Montreal

České Budějovice

Jihlava

Ostrava - Poruba

Prague

Tábor

Grenoble

Lyon

Nantes

Saint-Lô

Bologna

Brescia

Como

Pavia

Aguascalientes

Mexico City

Tijuana

Gdansk

Szczecin

Torun

Warsaw

Caguas

Bamaul

Kazan'

Krasnodar

Moscow

Nizhny Novgorod

Novosibirsk

Pyatigorsk

Ryazan

Saint Petersburg

Saratov

Smolensk

Sochi

Stavropol

Yekaterinburg

Chernivtsi

Dnipropetrovsk

Donetsk

Ivano-Frankivsk

Kharkiv

Kiev

Odesa

Uzhhorod

Vinnitsa

Zhytomyr

Sponsors
All Listed Sponsors
collaborator

Kureha Corporation

INDUSTRY

lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY